News ESMO 2019 – new data could unlock bigger market for PARP inh... AstraZeneca and GlaxoSmithKline could both benefit from new data that should widen the market for PARP inhibitors as first-l
News AZ/MSD’s PARP inhibitor shows promise as first-line ovarian ... AstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this time in first-line treatment of advanced ovarian cancer.
News AZ/MSD’s Lynparza sees positive results in prostate cancer AstraZeneca and MSD have announced positive phase III results for their PARP inhibitor Lynparza (olaparib) in metastatic castration-resistant prostate cancer (mCRPC).
Digital Asking the right questions around AI, with Brian Alexander, ... At BIO 2025, editor-in-chief Jonah Comstock spoke with Brian Alexander, CEO of Valo Health, about how he’s seeing the AI conversation evolve.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face